Literature DB >> 35737948

Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study.

Tara C Bouton1,2, Joseph Atarere2, Jacquelyn Turcinovic3,4, Scott Seitz5, Cole Sher-Jan3, Madison Gilbert2,6, Laura White7, Zhenwei Zhou7, Mohammad M Hossain3, Victoria Overbeck2,8, Lynn Doucette-Stamm9, Judy Platt10, Hannah E Landsberg10, Davidson H Hamer11,3,12, Catherine Klapperich9,10,13, Karen R Jacobson1,2, John H Connor5,3,13,4.   

Abstract

BACKGROUND: In January 2022, United States guidelines shifted to recommend isolation for 5 days from symptom onset, followed by 5 days of mask wearing. However, viral dynamics and variant and vaccination impact on culture conversion are largely unknown.
METHODS: We conducted a longitudinal study on a university campus, collecting daily anterior nasal swabs for at least 10 days for RT-PCR and culture, with antigen rapid diagnostic testing (RDT) on a subset. We compared culture positivity beyond day 5, time to culture conversion, and cycle threshold trend when calculated from diagnostic test, from symptom onset, by SARS-CoV-2 variant, and by vaccination status. We evaluated sensitivity and specificity of RDT on days 4-6 compared to culture.
RESULTS: Among 92 SARS-CoV-2 RT-PCR positive participants, all completed the initial vaccine series, 17 (18.5%) were infected with Delta and 75 (81.5%) with Omicron. Seventeen percent of participants had positive cultures beyond day 5 from symptom onset with the latest on day 12. There was no difference in time to culture conversion by variant or vaccination status. For 14 sub-study participants, sensitivity and specificity of day 4-6 RDT were 100% and 86% respectively.
CONCLUSIONS: The majority of our Delta- and Omicron-infected cohort culture-converted by day 6, with no further impact of booster vaccination on sterilization or cycle threshold decay. We found that rapid antigen testing may provide reassurance of lack of infectiousness, though guidance to mask for days 6-10 is supported by our finding that 17% of participants remained culture positive after isolation.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; Infection Dynamics; Omicron; SARS-CoV-2; Viral Infection

Year:  2022        PMID: 35737948      PMCID: PMC9278204          DOI: 10.1093/cid/ciac510

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  3 in total

1.  Return to exercise post-COVID-19 infection: A pragmatic approach in mid-2022.

Authors:  David C Hughes; John W Orchard; Emily M Partridge; Andre La Gerche; Carolyn Broderick
Journal:  J Sci Med Sport       Date:  2022-06-07       Impact factor: 4.597

2.  Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study.

Authors:  Miguel Garcia-Knight; Khamal Anglin; Michel Tassetto; Scott Lu; Amethyst Zhang; Sarah A Goldberg; Adam Catching; Michelle C Davidson; Joshua R Shak; Mariela Romero; Jesus Pineda-Ramirez; Ruth Diaz-Sanchez; Paulina Rugart; Kevin Donohue; Jonathan Massachi; Hannah M Sans; Manuella Djomaleu; Sujata Mathur; Venice Servellita; David McIlwain; Brice Gaudiliere; Jessica Chen; Enrique O Martinez; Jacqueline M Tavs; Grace Bronstone; Jacob Weiss; John T Watson; Melissa Briggs-Hagen; Glen R Abedi; George W Rutherford; Steven G Deeks; Charles Chiu; Sharon Saydah; Michael J Peluso; Claire M Midgley; Jeffrey N Martin; Raul Andino; J Daniel Kelly
Journal:  PLoS Pathog       Date:  2022-09-12       Impact factor: 7.464

3.  Clinical scoring system to predict viable viral shedding in patients with COVID-19.

Authors:  Sung Woon Kang; Heedo Park; Ji Yeun Kim; Sunghee Park; So Yun Lim; Sohyun Lee; Joon-Yong Bae; Jeonghun Kim; Seongman Bae; Jiwon Jung; Min Jae Kim; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Sung-Cheol Yun; Man-Seong Park; Sung-Han Kim
Journal:  J Clin Virol       Date:  2022-10-04       Impact factor: 14.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.